These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 17568687)
1. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability. Robinson DS; Amsterdam JD J Affect Disord; 2008 Jan; 105(1-3):15-23. PubMed ID: 17568687 [TBL] [Abstract][Full Text] [Related]
2. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. Feiger AD; Rickels K; Rynn MA; Zimbroff DL; Robinson DS J Clin Psychiatry; 2006 Sep; 67(9):1354-61. PubMed ID: 17017821 [TBL] [Abstract][Full Text] [Related]
3. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. Amsterdam JD; Bodkin JA J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814 [TBL] [Abstract][Full Text] [Related]
5. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. Amsterdam JD J Clin Psychiatry; 2003 Feb; 64(2):208-14. PubMed ID: 12633131 [TBL] [Abstract][Full Text] [Related]
6. Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale. Clayton AH; Campbell BJ; Favit A; Yang Y; Moonsammy G; Piontek CM; Amsterdam JD J Clin Psychiatry; 2007 Dec; 68(12):1860-6. PubMed ID: 18162016 [TBL] [Abstract][Full Text] [Related]
7. Transdermal selegiline: the new generation of monoamine oxidase inhibitors. Patkar AA; Pae CU; Masand PS CNS Spectr; 2006 May; 11(5):363-75. PubMed ID: 16641841 [TBL] [Abstract][Full Text] [Related]
8. Selegiline transdermal system: current awareness and promise. Pae CU; Lim HK; Han C; Neena A; Lee C; Patkar AA Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1153-63. PubMed ID: 17614182 [TBL] [Abstract][Full Text] [Related]
9. Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures. Pae CU; Bodkin JA; Portland KB; Thase ME; Patkar AA J Clin Psychiatry; 2012 May; 73(5):661-8. PubMed ID: 22697192 [TBL] [Abstract][Full Text] [Related]
10. Monoamine oxidase inhibitors: a new generation. Robinson DS Psychopharmacol Bull; 2002; 36(3):124-38. PubMed ID: 12473970 [TBL] [Abstract][Full Text] [Related]
11. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects. Azzaro AJ; Vandenberg CM; Blob LF; Kemper EM; Sharoky M; Oren DA; Campbell BJ J Clin Pharmacol; 2006 Aug; 46(8):933-44. PubMed ID: 16855078 [TBL] [Abstract][Full Text] [Related]
12. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Bodkin JA; Amsterdam JD Am J Psychiatry; 2002 Nov; 159(11):1869-75. PubMed ID: 12411221 [TBL] [Abstract][Full Text] [Related]
13. A critical appraisal of the selegiline transdermal system for major depressive disorder. Bied AM; Kim J; Schwartz TL Expert Rev Clin Pharmacol; 2015; 8(6):673-81. PubMed ID: 26427518 [TBL] [Abstract][Full Text] [Related]
14. Selegiline transdermal system: in the treatment of major depressive disorder. Frampton JE; Plosker GL Drugs; 2007; 67(2):257-65; discussion 266-7. PubMed ID: 17284087 [TBL] [Abstract][Full Text] [Related]
15. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials. Robinson DS; Gilmor ML; Yang Y; Moonsammy G; Azzaro AJ; Oren DA; Campbell BJ Psychopharmacol Bull; 2007; 40(3):15-28. PubMed ID: 18007565 [TBL] [Abstract][Full Text] [Related]
16. Critical appraisal of selegiline transdermal system for major depressive disorder. Cristancho MA; Thase ME Expert Opin Drug Deliv; 2016; 13(5):659-65. PubMed ID: 26837935 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials. Pae CU; Patkar AA; Jang S; Portland KB; Jung S; Nelson JC CNS Spectr; 2014 Aug; 19(4):324-9. PubMed ID: 24168807 [TBL] [Abstract][Full Text] [Related]
18. Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS). Jang S; Jung S; Pae C; Kimberly BP; Craig Nelson J; Patkar AA J Affect Disord; 2013 Dec; 151(3):854-9. PubMed ID: 24021959 [TBL] [Abstract][Full Text] [Related]
19. Selegiline transdermal system in major depressive disorder: profile report. Frampton JE; Plosker GL CNS Drugs; 2007; 21(6):521-4. PubMed ID: 17521230 [No Abstract] [Full Text] [Related]